TCG’s iPartners represents a new ideation advisory group comprised of leading academic investigators and biotech entrepreneurs. Working closely with TCG’s Swanson Fellows and our core investment team, this group is dedicated to crafting innovative new drug discovery company concepts, drawing on their deep scientific expertise, academic and industry networks, and entrepreneurial intuition.
The iPartners consist of Dr. Jennifer Doudna, Dr. Michael Fischbach, Dr. K. Christopher Garcia, and Dr. Micha Rapé.
Jennifer Doudna, PhD is a biochemist at the University of California, Berkeley and Founder and President of the Innovative Genomics Institute at UC Berkeley. Her groundbreaking development of CRISPR-Cas9, a genome engineering technology that allows researchers to edit DNA, earned her the 2020 Nobel Prize in Chemistry.
Michael Fischbach, PhD is an Associate Professor in the Departments of Bioengineering and Microbiology & Immunology at Stanford University, an Institute Scholar of Stanford ChEM-H, and the director of the Stanford Microbiome Therapies Initiative. He is a co-founder of Revolution Medicines.
K. Christopher Garcia, Ph.D is a Professor of Molecular and Cellular Physiology, and of Structural Biology at the Stanford University School of Medicine. He is a co-founder of Surrozen and the founder of Synthekine.
Micha Rapé, PhD is the Dr. K. Peter Hirth Chair of Cancer Biology and a Professor of Cell and Developmental Biology at the University of California, Berkeley. He is a pioneer in uncovering molecular mechanisms of cell fate determination, using posttranslational modification with ubiquitin as his starting point. He co-founded Nurix Therapeutics.
